Related Experiment Video
Updated: Aug 17, 2026

Assessing Therapeutic Angiogenesis in a Murine Model of Hindlimb Ischemia
Published on: June 8, 2019
Dual-pathway inhibition in patients with chronic limb-threatening ischemia requiring reintervention for
Burak Teymen1, Mehmet Emin Öner2, Yiğit Erdağ3
1Department of Cardiology, Emsey Hospital, Kurtköy Pendik, 34912, Istanbul, Turkey. burakteymen@yahoo.com.
Insights
New oral anticoagulant (NOAC) therapy significantly improved outcomes for patients undergoing below-the-knee intervention, reducing reocclusion and revascularization rates compared to dual-antiplatelet therapy (DAPT). This NOAC approach offers a promising alternative for managing chronic limb-threatening ischemia.
Area of Science:
- Vascular Surgery
- Interventional Cardiology
- Pharmacology
Background:
- Chronic limb-threatening ischemia (CLTI) poses significant challenges, often requiring complex interventions.
- Endovascular intervention for below-the-knee (BTK) occlusions necessitates strategies to maintain patency and prevent reintervention.
- Optimizing antithrombotic therapy after BTK intervention is crucial for long-term clinical success.
Purpose of the Study:
- To evaluate the impact of new oral anticoagulant (NOAC) therapy on clinical outcomes following endovascular intervention for BTK occlusions requiring reintervention.
- To compare the efficacy and safety of NOAC plus clopidogrel versus dual-antiplatelet therapy (DAPT) in patients with CLTI undergoing BTK reintervention.
Main Methods:
- Retrospective analysis of 64 patients undergoing endovascular reintervention for BTK occlusions.
- Patients were divided into two groups: NOAC (rivaroxaban 2.5 mg BID + clopidogrel) and DAPT (clopidogrel + aspirin).
- Primary endpoints included target vessel reocclusion and target lesion revascularization (TLR) at 1-year follow-up; secondary endpoints were amputation rates and major bleeding events.
Main Results:
- The NOAC group demonstrated significantly lower rates of TLR (10.7% vs. 32.4%, p=0.043) and target vessel reocclusion (17.8% vs. 41.2%, p=0.048) at 1 year compared to the DAPT group.
- Amputation rates were numerically lower in the NOAC group (3.6% vs. 11.7%), although not statistically significant (p=0.245).
- No significant difference in major bleeding events was observed between the NOAC and DAPT groups.
Conclusions:
- Incorporating NOAC therapy (rivaroxaban + clopidogrel) significantly improves patency and reduces revascularization rates after endovascular BTK reintervention in CLTI patients.
- NOAC-based therapy appears to be a safe and effective alternative to DAPT, with comparable bleeding risk.
- Further prospective studies are warranted to confirm these findings and optimize antithrombotic strategies for BTK interventions.
Abstract:
Our study aimed to assess the influence of incorporating new oral anticoagulant (NOAC) therapy on clinical outcomes among patients who underwent endovascular intervention for below-the-knee (BTK) occlusions necessitating reintervention. The inclusion criteria encompassed patients with chronic limb-threatening ischemia (CLTI) and had undergone a successful endovascular intervention for BTK artery occlusion, necessitating reintervention. Patients who underwent endovascular interventions for BTK reocclusion were compared to those who received dual-pathway inhibition with NOAC (rivaroxaban 2.5 mg 2 × 1) and clopidogrel (NOAC group), or dual-antiplatelet therapy with clopidogrel and aspirin (DAPT group). The primary endpoints were target vessel reocclusion and target lesion revascularization (TLR) at the 1-year follow-up, while major and minor amputations served as the secondary endpoint. Additionally, a one-year comparison was conducted between the two groups for major bleeding events. 64 patients in our clinic treated with endovascular reintervention (NOAC = 28, DAPT = 34). The TLR rate is 10.7% in NOAC group (N = 3) and 32.4% in DAPT group (N = 11, p = 0.043). The target vessel reocclusion rate is 17.8% in NOAC group (N = 5) and 41.2% in DAPT group (N = 14, p = 0.048). Minor or major amputation rate at 1-year follow-up was 3.6% in NOAC group (N = 1) and 11.7% in DAPT group (N = 4, p = 0.245). The patency rate is significantly higher, and the TLR rate is significantly lower in the NOAC group compared to the DAPT group, with no significant difference in major bleeding between the two groups. Although no statistically significant difference exists in amputation rates, a numerical distinction is evident.
More Related Videos
07:25Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia
Published on: September 22, 2020
08:16High-Resolution Three-Dimensional Imaging of the Footpad Vasculature in a Murine Hindlimb Gangrene Model
Published on: March 16, 2022
Related Concept Videos
Peripheral Artery Disease I: Introduction
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
Peripheral Artery Disease III: Interprofessional Care
Peripheral Artery Disease IV: Nursing Management
Peripheral Artery Disease V: Postoperative Nursing Management